Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 4Lymphoid 1

Conditions

Lymphoma 549Precursor Cell Lymphoblastic Leukemia-Lymphoma 511Lymphoma, Non-Hodgkin 437Lymphoma, Follicular 405Lymphoma, Large B-Cell, Diffuse 392Leukemia, Lymphocytic, Chronic, B-Cell 392Lymphoma, B-Cell 248Lymphoma, Mantle-Cell 224Hodgkin Disease 209Recurrence 205Leukemia, Myeloid, Acute 199Leukemia 196Multiple Myeloma 185Burkitt Lymphoma 185Lymphoma, B-Cell, Marginal Zone 170Neoplasms 153Myelodysplastic Syndromes 134Hematologic Neoplasms 115Waldenstrom Macroglobulinemia 103Lymphoma, T-Cell, Peripheral 86Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 83Lymphoma, T-Cell 82Lymphoma, T-Cell, Cutaneous 67Leukemia, Myelogenous, Chronic, BCR-ABL Positive 63Mycosis Fungoides 57Leukemia, Biphenotypic, Acute 55Breast Neoplasms 55Leukemia, B-Cell 52Myeloproliferative Disorders 50Lymphoproliferative Disorders 47

Interventions

BAY 1895344 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rhabdomyosarcoma, Alveolar × Lymphoid × 1 year × Clear all
NCT05071209 2026-01-23

Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
31 enrolled 14 charts
LymphoidSarcoma

Lymphoma, Sarcoma, Ewing, Rhabdomyosarcoma, Alveolar

Data powered by HemOnc (CC BY 4.0) Colophon âš¡